Begin with the decision, rather than the number

A laboratory result can feel more definite than a symptom. A number arrives with a reference range, sometimes a coloured flag, and the apparent authority of measurement. Yet precision of reporting is different from completeness of meaning. Faecal calprotectin is useful because it offers information about intestinal inflammation; it becomes misleading when asked to identify every cause of bowel discomfort or to pronounce the whole digestive system healthy. The first question is therefore practical: what decision was this test ordered to support?

There are two particularly different settings. Someone without a diagnosis may be undergoing assessment for persistent lower bowel symptoms. Someone with established inflammatory bowel disease, or IBD, may be monitoring treatment and disease activity. A result obtained in the second setting cannot simply be imported into the first. The person, previous investigations and intended action are part of the test, even though they are not printed beside its numerical value.

In my approach to health writing, context means preserving these distinctions rather than collecting more measurements without a plan. Before interpreting a report, identify who will review it, what symptoms prompted it and whether a repeat test, specialist assessment or change in treatment was being considered. These questions do not diminish the science. They make the science usable.

Evidence: what the marker can establish

NICE recommends faecal calprotectin as an option to support assessment of inflammatory bowel disease versus non-inflammatory conditions such as irritable bowel syndrome, or IBS, in an appropriate lower gastrointestinal symptom pathway. Its guidance excludes situations in which bowel cancer is suspected. Calprotectin should be combined with other clinical information, and the guidance explicitly warns against false reassurance when a cancer assessment is needed. A reassuring stool marker does not cancel an independently concerning history.

Calprotectin is a sensitive but non-specific marker: an elevated result is evidence to investigate, rather than a label naming a single disease. University Hospitals of North Midlands lists infection, non-steroidal anti-inflammatory medicines and other bowel diseases among possible explanations for elevation. The logic matters. If several processes can raise a marker, observing that marker cannot, by itself, identify which process occurred. The result may strengthen one explanation while leaving competing explanations open.

IBS and IBD are also not interchangeable descriptions of symptom severity. IBS can substantially impair daily life even when this inflammation marker is low. Conversely, a person with known IBD may feel relatively well while objective assessment identifies continuing activity. Neither suffering nor inflammation can be reduced to the other. A useful consultation asks about both, allowing symptom relief and disease monitoring to remain related but distinct goals.

Evidence: monitoring established IBD is a separate use

The American Gastroenterological Association recommends combining symptoms and biomarkers when monitoring Crohn’s disease. In a person in symptomatic remission, on stable therapy, with recent confirmation of endoscopic remission and no change in clinical status, its guidance describes how low calprotectin and normal inflammatory blood markers can help avoid routine endoscopic reassessment. Those conditions are not decorative qualifications. They explain why the same result carries different weight in a newly symptomatic person who has never had a diagnosis.

The AGA ulcerative colitis guideline similarly combines symptoms with biomarkers. It distinguishes apparent remission with reassuring markers from remission with elevated markers, and it advises further assessment in several discordant or mildly symptomatic situations rather than automatic treatment adjustment. The often quoted value of 150 micrograms per gram belongs to particular monitoring recommendations. It is not a universal boundary that independently diagnoses IBD, excludes all bowel disease or authorises somebody to alter prescribed treatment.

The CALM randomised trial adds an important piece of evidence. In selected patients with early active Crohn’s disease, a treatment strategy using symptoms together with biomarkers achieved the trial’s endoscopic healing outcome more often than a strategy driven by symptoms alone. That supports structured clinical monitoring. It does not show that repeated self-testing, or chasing the lowest possible number through diet and supplements, produces the same benefit. The tested intervention was a supervised treatment algorithm, not measurement in isolation.

Practical implications: prepare a history that makes the result interpretable

When arranging testing, give the clinical team a clear account of the symptom pattern: when it began, whether it is changing and how it affects eating, bowel function and ordinary activities. Include recent gastrointestinal infection, relevant diagnoses and the medicines actually taken, including medicines bought without a prescription. A medicine omitted from the history can become an explanation omitted from the interpretation. This is a reason for an accurate list, not a reason to stop necessary treatment independently.

NSAIDs and proton-pump inhibitors can be relevant to an equivocal result, as Scottish NHS guidance notes, but decisions about withholding or substituting them belong with the prescribing clinician. Laboratories and services use different pathways, with different thresholds and repeat-testing intervals. Follow the instructions attached to the actual sample and local service rather than combining preparation advice from several websites. If there is a practical difficulty collecting or returning the sample, ask the laboratory or clinical team before improvising.

It is worth writing down the agreed next step before leaving the appointment. Who communicates the result? When should you make contact if nothing arrives? What would trigger referral, and what should happen if the number is reassuring but symptoms continue? These ordinary arrangements prevent a common failure of testing: a result exists, yet nobody knows what decision follows. Care becomes more coherent when information has both an interpreter and a route to action.

Practical implications: interpret disagreement instead of choosing a favourite signal

A person with severe symptoms and a reassuring marker may feel disbelieved; someone who feels well with an elevated marker may feel that a test is creating illness. Both reactions are understandable. The clinical task is to examine disagreement, not to declare that symptoms or laboratory findings always win. A clinician may review the original diagnosis, disease location, recent assessment, alternative causes and whether further investigation would resolve the uncertainty. No single step is appropriate for every person.

Trends can be informative when the testing method and clinical setting are comparable, but a series of results still needs an agreed purpose. Ask what change would be meaningful enough to alter management. A small movement can become psychologically large when someone checks it repeatedly without knowing whether the difference matters. The aim is to connect monitoring with a treatment objective, rather than allowing a fluctuating number to become a daily verdict on personal behaviour.

For established IBD, do not stop maintenance medicine because bowel symptoms settle or a stool result improves. Equally, do not increase treatment or add an anti-inflammatory supplement because a single result is flagged. AGA guidance specifically favours confirmation in several settings before treatment adjustment. The useful response is a discussion about what has changed, what remains uncertain and whether the planned assessment is still the right one.

Limits and unanswered questions: a threshold is not the whole patient

An unanswered question in an individual consultation is often more important than a general debate about the best numerical cut-off. Is the elevation persistent? Could a recent illness have contributed? Does the result fit previous observations for this person? Is the proposed test being used for initial assessment, treatment monitoring or a postoperative question? These distinctions help explain why local protocols differ without implying that every laboratory is contradicting every other laboratory.

There is also a limit to what a normal result can promise. NICE’s warning about suspected cancer is especially important: this marker should not be used to divert someone from the appropriate cancer investigation pathway. New bleeding, progressive unexplained changes or other concerning symptoms require clinical assessment, whether or not an earlier calprotectin result looked reassuring. If a person is acutely unwell, the priority is timely care rather than waiting for a routine repeat sample.

More testing is not automatically more understanding. A test has value when its result can reasonably change an action, clarify a question or establish a useful baseline. If nobody can explain what either a high or low result would change, the decision to test deserves another conversation. The aim is not to minimise investigation at any cost, but to prevent measurement from becoming a substitute for clinical reasoning.

A framework for retaining agency without inventing certainty

The wider Nicolaev Medicine perspective invites attention to biological context and the relationship between systems. Here I use that perspective as a discipline of questioning: identify the purpose, respect the measurement and keep its limits visible. It is an author framework, not a validated diagnostic method. Terms such as coherence cannot replace endoscopy, clinical assessment or evidence-based IBD treatment, and changes in emotional state cannot be assumed to explain a stool inflammation marker.

The strongest form of personal involvement is often less dramatic than a new protocol. Keep the history accurate, attend the agreed review, report important changes and ask for explanations that distinguish what is known from what is being checked. A person does not need to become their own gastroenterologist to participate intelligently. They need a clear account of the question, an honest interpretation of the evidence and a plan that remains responsive to their actual condition.

Related reading

Author and medical note

Written by . This is general educational writing and author analysis, not a personal diagnosis or treatment plan. Discuss symptoms, treatment changes and supplement interactions with a qualified clinician. No independent medical review is claimed.

References

  1. NICE: Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel—considerations
  2. AGA: The role of biomarkers for the management of Crohn’s disease
  3. AGA: The role of biomarkers for the management of ulcerative colitis
  4. Colombel and colleagues: Effect of tight control management on Crohn’s disease (CALM), randomised trial, 2017
  5. University Hospitals of North Midlands: Calprotectin (faecal), laboratory guidance
  6. NHS Scotland Right Decisions: Calprotectin diagnostic education toolkit

Gabriel Nicolaev – CyGuru